Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
Clinical trial NCT02257424 · COMPLETED
Trial details
- NCT number
- NCT02257424
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-01
- Primary completion
- 2021-10-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.